Skip to main content
Journal cover image

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.

Publication ,  Journal Article
Engelhardt, BG; Holland, DW; Brandt, SJ; Chinratanalab, W; Goodman, SA; Greer, JP; Jagasia, MH; Kassim, AA; Morgan, DS; Ruffner, KL; Wolff, S ...
Published in: Leuk Lymphoma
September 2007

Between January 1990 and April 2001, 115 patients received high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) for relapsed or refractory Hodgkin lymphoma (HL). With a median follow-up of 58 months (range, 1 - 175 months), 5-year progression-free survival (PFS) and overall survival (OS) were 46% and 58%, respectively. Twelve patients with primary refractory disease had a 5-year PFS of 41% and OS of 58%, not significantly different from those of the remaining cohort. Early and overall regimen related mortality were 7% and 16%, respectively. Male gender (P = 0.04) and a time to relapse (TTR) < 12 months (P = 0.03) were associated with decreased OS by univariate analysis. In multivariate analysis, TTR < 12 months remained statistically significant (P = 0.04). We have confirmed that HDT and ASCT result in long-term survival for a proportion of patients with relapsed or refractory HL. All patients, including those with primary refractory disease, benefited from HDT and ASCT.

Duke Scholars

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

September 2007

Volume

48

Issue

9

Start / End Page

1728 / 1735

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Recurrence
  • Prognosis
  • Neoplasms, Second Primary
  • Middle Aged
  • Male
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Engelhardt, B. G., Holland, D. W., Brandt, S. J., Chinratanalab, W., Goodman, S. A., Greer, J. P., … Stein, R. S. (2007). High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk Lymphoma, 48(9), 1728–1735. https://doi.org/10.1080/10428190701534374
Engelhardt, Brian G., Derek W. Holland, Stephen J. Brandt, Wichai Chinratanalab, Stacey A. Goodman, John P. Greer, Madan H. Jagasia, et al. “High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.Leuk Lymphoma 48, no. 9 (September 2007): 1728–35. https://doi.org/10.1080/10428190701534374.
Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk Lymphoma. 2007 Sep;48(9):1728–35.
Engelhardt, Brian G., et al. “High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.Leuk Lymphoma, vol. 48, no. 9, Sept. 2007, pp. 1728–35. Pubmed, doi:10.1080/10428190701534374.
Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, Jagasia MH, Kassim AA, Morgan DS, Ruffner KL, Schuening FG, Wolff S, Bitting R, Sulur P, Stein RS. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk Lymphoma. 2007 Sep;48(9):1728–1735.
Journal cover image

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

September 2007

Volume

48

Issue

9

Start / End Page

1728 / 1735

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Recurrence
  • Prognosis
  • Neoplasms, Second Primary
  • Middle Aged
  • Male
  • Immunology
  • Humans